CEO: Barrie Ward

Advent Contact: Shahzad Malik

First in class small molecule modulators of DNA repair mechanisms

KuDos' platform, developed by Professor Steve Jackson, discovered oncology therapies based upon the inhibition of DNA repair. Lynparza™ (Olaparib), was the first approved PARP inhibitor for women with BRCA-mutated advanced ovarian cancer who have been treated with three or more lines of chemotherapy.

Advent invested in Series A in 1999. KuDos was acquired by Astra Zeneca in 2005.